Prostate cancer: only one in four men with metastatic disease gets recommended chemotherapyBMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m120 (Published 13 January 2020) Cite this as: BMJ 2020;368:m120
- Jacqui Wise
A national audit shows that only one in four men with advanced prostate cancer receives life prolonging chemotherapy despite its recommendation by the National Institute for Health and Care Excellence (NICE).
The National Prostate Cancer Audit’s annual report 2019 for England and Wales,1 published by the Royal College of Surgeons, reported for the first time on the use of primary docetaxel in metastatic disease. It found that only 27% of men with widespread disease received docetaxel, ranging from 0% to 39% by NHS providers in England.
Noel Clarke, consultant urological surgeon, and Heather Payne, consultant clinical oncologist, who were joint clinical leads for the audit, said that the …